Skip to NavigationSkip to content

Incyte's ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis

Published on 07/04/20 at 11:39am

Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations of ruxolitinib in the treatment of mild-to-moderate atopic dermatitis.

The findings from two studies were presented at the Revolutionizing Atopic Dermatitis Virtual Symposium on Sunday; both met their main goal, with a greater proportion of ruxolitinib patients achieving an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline after eight weeks of treatment.

In the first study, the data showed that 40.4% and 52.2% of patients receiving ruxolitinib 0.75% and 1.5% respectively achieved at least a score of 4 on the Itch Numerical Rating Scale at eight weeks, representing a clinically meaningful reduction in itch. In the second study, this was recorded as 42.7% and 50.7% of patients respectively by the same point.

Furthermore, ruxolitinib users saw a “significantly greater” reduction on the Scale within 12 hours of treatment compared to non-medicated cream.

Dr Jim Lee, Incyte’s Group Vice President, Inflammation & AutoImmunity, said that the cream “significantly reduced both the skin inflammation and itch associated with atopic dermatitis. The reduction in itch can potentially improve key disease-related and quality of life outcomes for patients living with atopic dermatitis.”

He added: “We are pleased to share these important data with the dermatology community, as they support the potential of ruxolitinib cream to become an important antipruritic and anti-inflammatory treatment option for patients with atopic dermatitis, and we look forward to submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration later this year.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches